Peptide Prices Per mg in 2026: What 56 Vendors Charge for 24 Peptides

The median milligram of NAD+ costs 12 cents across the 44 vendors we track. The median milligram of IGF-1 LR3 costs $80.00 across 43. Both sit on the same shelf under the same "research peptide" label, and one costs 667 times the other. We price 920 vendor listings across 26 peptides every week, and the per-milligram number tells you more about what you are actually buying than any product page will. Here is the whole index, refreshed October 11, with our take on where a cheap milligram is great news and where it deserves a second look.

The index: 24 peptides, lowest and median price per mg

The method is simple. For every vendor on our board we take the cheapest in-stock size of each peptide, divide price by milligrams, and keep that one number per vendor. Blends are excluded, shipping is excluded, and two thin markets (dihexa with 3 sellers, oxytocin with 1) are left off because a median of three is a coin flip.

Three things jump out. The bulk of the catalog, 19 of 24 peptides, has a median between $3.00 and $9.00 per milligram, so if someone quotes you a number in that band for a common peptide, you are being charged the market rate. The floor and the median are usually 1.5 to 3 times apart, which means the cheapest listing on a crowded peptide is real money saved. And a single peptide sits an order of magnitude above everything else. Every number in that table is live on the matching page under /peptides, vendor by vendor.

Why one milligram costs 667 times another

The spread is chemistry before it is anything else. NAD+ is a small molecule, a dinucleotide with a molecular weight of 663 (PubChem lists it as C21H27N7O14P2), and it gets made and sold by the gram. Our cheapest listing is a 1,000 mg vial. GHK-Cu is a three-amino-acid chain with a copper ion attached, and a 100 mg vial is the normal retail size. A dollar a milligram would be the very top of the market for either.

Most of the middle of the table is built the same way: solid-phase synthesis, one amino acid coupled at a time onto a resin, then cleaved and purified by HPLC. Length is what makes that expensive. The standard worked example runs like this: at 99% yield per coupling step, a 26-residue peptide comes off the resin at about 77% crude yield; drop each step to 95% and the overall yield falls to 25%. Every residue you add is another step that has to go nearly perfectly, which is why chains of 40 to 50 residues are described as pushing the limits of the method and why the deletion sequences from any missed coupling make purification harder on long peptides. BPC-157 is a short chain, squarely in the comfortable zone, and its median of $5.50 reflects that.

IGF-1 LR3 is the outlier because it is an 83-amino-acid protein, produced recombinantly in E. coli, then folded, purified, and sold in 1 mg vials. The cheapest publicly priced milligram we track is $34.95 and the median is $80.00. Roughly 15 BPC-157 milligrams for one IGF-1 LR3 milligram is the honest exchange rate. We wrote up the full seller ranking in our IGF-1 LR3 supplier guide.

The GLP-1 cluster, where seller count sets the price

The six incretin-class peptides tell a cleaner story than the rest of the table. Tirzepatide has 16 sellers and the lowest median of the group at $4.81. Semaglutide, with 17 sellers, sits at $6.00, and retatrutide, with 22, at $6.98. Then the newer dual agonists arrive with fewer than ten sellers each: mazdutide at $9.00 (8 vendors) and survodutide at $12.00 (9 vendors). Cagrilintide, an amylin analog that tends to get sold alongside them, is at $10.00 across 21.

Our read is that the price of these molecules tracks seller count more tightly than anything about the molecule itself. Survodutide costs two and a half times tirzepatide at the median, and the gap is competition. As the survodutide and mazdutide seller counts climb toward twenty over the next year, we expect their medians to settle into the same $5 to $7 band the first wave now occupies. If you are buying one of the newest ones today, you are paying an early-adopter premium, and it will fade.

The vial-size lever most buyers skip

Vial size moves your per-milligram cost more than vendor choice does on the crowded peptides. Across our BPC-157 listings, the median 5 mg vial works out to $7.80 per milligram and the median 10 mg vial to $5.50, a 30% cut for stepping up one size. The 10 mg BPC-157 vial alone has 35 in-stock sellers, running from $39.20 up to a median of $54.99. Go bigger and the floor drops again: NuLife Peptides, a Finnrick-tested US seller rated 8.3 out of 10 on our board, lists a 40 mg vial at $90.00, which is $2.25 per milligram and the lowest BPC-157 price we track.

The catch is practical. Lyophilized powder stores well, but a reconstituted vial has a shelf window, so buy the size you will actually draw down within it. Our storage and reconstitution guide covers the timing.

Cheap milligrams we would happily point you to

A low price with a third-party certificate behind it is the best thing in this market, so here are the floors we checked in stock this week and would send people to.

Every link above lands on the vendor scorecard, so you can confirm the score, the lab tier, and the price before you buy.

How we build these numbers, and what they leave out

The pipeline re-scrapes every tracked vendor weekly, parses each size, computes dollars per milligram, and drops anything the vendor marks out of stock. Price is one of six inputs to our score, weighted at 25%, behind the quality of the certificate of analysis at 30%. The full rubric is public in how we score vendors, and how to read a peptide COA covers what a good certificate looks like.

What the index leaves out: shipping (a $10 vial with $20 shipping is a $30 vial), discount codes, and bulk tiers beyond the listed sizes. It also says nothing about purity. A milligram price is only meaningful next to the certificate for the batch, which is why the table pairs best with the lab tier on each scorecard.

One regulatory note for context. Everything above is sold for research use. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) for the 503A bulks list. Those recommendations are advisory, and formal rulemaking still has to happen before anything changes. We track it in our FDA reclassification explainer.

Sources